Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Free Report) has received a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $4.50.
A number of research firms have recently issued reports on LYRA. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of Lyra Therapeutics in a research report on Thursday, August 15th. William Blair raised Lyra Therapeutics to a “hold” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lyra Therapeutics in a research report on Thursday, August 15th.
View Our Latest Stock Report on LYRA
Lyra Therapeutics Stock Performance
Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.43 million. Lyra Therapeutics had a negative net margin of 5,570.88% and a negative return on equity of 102.22%. As a group, equities analysts predict that Lyra Therapeutics will post -1.15 earnings per share for the current fiscal year.
Institutional Trading of Lyra Therapeutics
A hedge fund recently raised its stake in Lyra Therapeutics stock. Vanguard Group Inc. lifted its position in shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA – Free Report) by 38.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,481,481 shares of the company’s stock after buying an additional 410,021 shares during the quarter. Vanguard Group Inc. owned about 2.43% of Lyra Therapeutics worth $9,215,000 as of its most recent SEC filing. Institutional investors and hedge funds own 95.62% of the company’s stock.
About Lyra Therapeutics
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Further Reading
- Five stocks we like better than Lyra Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Energy and Oil Stocks Explained
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- What Investors Need to Know About Upcoming IPOs
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.